Stay updated with breaking news from Ios Gmb. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EQS-News: invIOs GmbH / Key word(s): Study invIOs starts further clinical trial of APN401, novel cell therapy against solid cancers, and secures major Austrian grant funding 05.09.2023 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement. invIOs starts further c...
A small molecule compound has shown to induce strong anti-tumor immune responses – an area where medical need is high.
INV501, a potentially first-in-class compound, induces strong anti-tumor immune responses in preclinical models in different solid tumor indicationsTreatment with INV501 significantly inhibits tumor growth, extends survival and increases cure rates even after end of treatmentINV501 is an orally available compound with good bioavailability and favorable pharmacokinetic profile VIENNA, Austria, June 19, 2023 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company develop
EQS-News: invIOs GmbH / Key word(s): Conference invIOs presents promising new clinical data in solid tumors from autologous cell therapy APN401 at AACR Annual Meeting 2023 18.04.2023 / 15:00 CET/CEST The issuer is solely responsible for the content of this announcement. invIOs presents promising...
EQS-News: invIOs GmbH / Key word(s): Conference invIOs to present at Biotech Showcase 14.12.2022 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. invIOs to present at Biotech Showcase Vienna, Austria, 14 December 2022: invIOs GmbH (“invIOs”), a privately he...